Stockreport

Genentech buys Regor's CDK inhibitors in $850m deal [Yahoo! Finance]

Exscientia Plc - American Depositary Shares  (EXAI) 
PDF Pharmaceuticals' portfolio of breast cancer cyclin-dependent kinase (CDK) inhibitors in an $850m deal. The deal, anticipated to close in Q4 2024, was unveiled by Genen [Read more]